 |
市场调查报告书
商品编码
1805548
mRNA 技术拓展製药领域mRNA Technologies Expanding Pharma Horizons |
||||||
本报告全面分析了 mRNA 技术在药物研发中的发展，并专注于其在 COVID-19 疫苗以外的应用。报告探讨了基于 mRNA 的疫苗和疗法的科学和商业进展，包括递送平台和生产过程的进步，以及环状 RNA 和自扩增 RNA 等新型疗法的出现。报告还重点介绍了人工智慧、奈米技术和基因编辑如何推动 mRNA 设计和应用的创新，并评估了塑造该领域的监管和市场力量。本报告将深入探讨各种 mRNA 格式的优点和限制、标靶递送和免疫原性的课题，以及 mRNA 技术在个人化癌症疫苗、罕见疾病和下一代基因编辑疗法等领域的未来潜力。
主要的问题
- 1.mRNA 技术如何影响疫苗和疗法的研发？
- 2.与线性 mRNA 相比，各种 mRNA 模式的优缺点是什么？
- 3.要充分发挥 mRNA 技术的潜力，必须面对哪些课题？
- 4.环状 RNA、自扩增 RNA、碱基编辑和 CRISPR 等新兴技术将如何影响 mRNA 模式？
- 5.基于 mRNA 的疫苗和治疗方法的开发将如何影响 mRNA 模式？最新进展
- 6.mRNA 技术未来应用于更广泛疾病的潜力
- 7.製造和交付方面的进步如何提高 mRNA 产品的品质和可近性？
- 8.开发和商业化基于 mRNA 的产品需要哪些监管考量？
- 9.人工智慧和机器学习等颠覆性技术如何加速 mRNA 创新？
- 10.mRNA 治疗领域的主要市场驱动力和投资趋势
主要企业
|
|
参加专家的一部分清单
- Advarra(美国)生物安全性服务担当执行董事
- Circio Holding ASA (挪威)CEO
- Sensible Biotechnologies(英国)CSO兼一起同成立者
- Sensible Biotechnologies(英国)CEO兼一起同成立者
调查手法:
檔案报告是基于独立、简洁的分析，这些分析源自于专有的产业研究以及对产业意见领袖的深入访谈。该报告对製药企业高管需要了解的关键发展和市场趋势进行了详细分析，以应对未来的机会和课题。每份报告的重点都基于对二手文献的回顾和已发现的知识差距。基于这些初步研究，我们制定了基于证据、专家指导的讨论指南，以确保我们的研究能够解答最重要的问题。此外，我们采用严格的筛选标准，以确保受访者拥有就该主题发言所需的经验、知识和地位。
我们的报告有何特别之处？
FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供深入可行的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助客户了解新兴趋势并有效应对复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖 (KOL) 的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访谈和数据，以及持续的市场监测，确保您能够全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域，并提供医生情报，包括关键意见领袖洞察和定量医生调查，以及行业专家对医疗事务、数位健康、销售和营销、市场准入等领域问题的看法，使您能够做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。
This report provides a comprehensive analysis of the evolving landscape of mRNA technologies in pharmaceutical development, with a focus on their impact beyond COVID-19 vaccines. It examines the scientific and commercial progress of mRNA-based vaccines and therapeutics, including advances in delivery platforms, manufacturing and the emergence of novel modalities, such as circular RNA and self-amplifying RNA. The report also highlights how AI, nanotechnology and gene editing are driving innovation in mRNA design and application, while assessing the regulatory and market forces shaping the sector. Gain insights into the advantages and limitations of different mRNA formats, the challenges of targeted delivery and immunogenicity and the future potential of mRNA technologies in areas such as personalised cancer vaccines, rare diseases and next-generation gene editing therapies.
Key Questions Answered:
- 1. How has mRNA technology impacted the development of vaccines and therapeutics?
- 2. What are the advantages and disadvantages of different mRNA modalities compared to linear mRNA?
- 3. What challenges must be addressed to fully realise the potential of mRNA technologies?
- 4. How might novel technologies like circular RNA, self-amplifying RNA, base editing and CRISPR influence the mRNA landscape?
- 5. What are the latest trends in mRNA-based vaccine and therapeutic development?
- 6. What future opportunities exist for applying mRNA technology to a broader range of diseases?
- 7. How are advances in manufacturing and delivery improving mRNA product quality and accessibility?
- 8. What regulatory considerations are shaping the development and commercialisation of mRNA-based products?
- 9. How are disruptive technologies, such as AI and machine learning, accelerating mRNA innovation?
- 10. What are the key market drivers and investment trends in the mRNA therapeutics sector?
Key Companies:
|
|
Partial List of Participating Experts:
- Executive Director of Biosafety Services, Advarra, US
- CEO, Circio Holding ASA, Norway
- CSO and co-founder, Sensible Biotechnologies, UK
- CEO and co-founder, Sensible Biotechnologies, UK
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
日本女性健康市场报告（按年龄组别类型、应用、配销通路和地区）2025-2033
女性健康药品市场（按类型、药物、应用和地区）：未来预测（2026-2032 年）女性健康软体市场规模（按类型、应用、地区、范围和预测）
治疗妇女疾病的药物：技术与全球市场
依药物、适应症、年龄层、最终用户、地区、机会和预测对全球女性健康治疗市场进行评估（2018 - 2032 年）女性健康药物的按印度市场评估:药物，各适应症，各年龄层，各终端用户，各地区，机会，预测(2018年度～2032年度)
女性健康治疗市场规模、份额和增长分析（按年龄、药物、分销管道、应用和地区）- 行业预测 2025-20322025-2033 年按年龄组别类型、应用、配销通路和地区分類的女性健康市场报告
全球女性健康市场规模、份额和趋势分析报告：按应用、药物类别、年龄、地区和细分市场预测（2025-2030）美国女性健康市场规模、份额、趋势分析报告：按应用、年龄、药物类别、细分市场预测，2025-2030 年